Addex officer reports stock-option holdings

Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares.

Rhea-AI Filing Summary

Addex Therapeutics Ltd. principal accounting officer Lenaic Nathanael Teyssedou filed an initial ownership report showing multiple stock-option awards over Addex common shares. These options are rights to buy shares at fixed prices and represent existing compensation grants, not new share purchases or sales.

The filing lists several option grants with exercise prices of $0.1660, $0.0550, and $0.0640 per share, expiring between 2027 and 2034. According to the footnotes, each option gives the right to buy one ADXN share, vesting in equal monthly installments over four years, and the exercise prices are reported in U.S. dollars using a $1.2769 per CHF $1.00 exchange rate as of March 12, 2026.

Insider Trade Summary

8 transactions reported

Mixed 8 txns

Insider Teyssedou Lenaic Nathanael

Role PRINCIPAL ACCOUNTING OFFICER

Type	Security	Shares	Price	Value
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--
holding	Stock-option (Right to Buy)	--	--	--

Holdings After Transaction: Stock-option (Right to Buy) — 602,908 contracts (Direct)

Footnotes (2)

1. F1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.
2. F2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Teyssedou Lenaic Nathanael

(Last) (First) (Middle)

CHEMIN DES MINES 9

(Street)

GENEVA CH-1202

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Addex Therapeutics Ltd. [ ADXN ]

3a. Foreign Trading Symbol
[ADXN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRINCIPAL ACCOUNTING OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock-option (Right to Buy)	01/01/2018(1)	12/31/2027	Common Stock	37,770	$0.166(2)	D
Stock-option (Right to Buy)	06/01/2018(1)	05/31/2028	Common Stock	59,530	$0.166(2)	D
Stock-option (Right to Buy)	04/01/2020(1)	03/31/2030	Common Stock	10,000	$0.166(2)	D
Stock-option (Right to Buy)	05/17/2021(1)	05/16/2031	Common Stock	30,000	$0.166(2)	D
Stock-option (Right to Buy)	04/12/2022(1)	04/11/2032	Common Stock	65,620	$0.166(2)	D
Stock-option (Right to Buy)	10/05/2022(1)	10/04/2032	Common Stock	90,529	$0.166(2)	D
Stock-option (Right to Buy)	05/12/2023(1)	05/11/2033	Common Stock	208,974	$0.055(2)	D
Stock-option (Right to Buy)	01/08/2024(1)	01/07/2034	Common Stock	100,485	$0.064(2)	D

Explanation of Responses:

1. The stock-options vest on equal monthly installments over a 4-year period beginning at the exercisable date. Each stock-option grants to right to purchase one ADXN share listed on SIX Swiss Exchange.

2. The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $ 1.2769 per CHF 1.00 as of March 12, 2026.

	/s/ Lenaic Nathanael Teyssedou	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)